

**Table S1** Basic characteristics of 112 early-stage PDAC patients<sup>a</sup>

Variables	Patients (n=112)	Overall survival, No. of events	MST (days)	HR (95% CI)	Log-rank P
<b>Age(years)</b>					
≤60	38	20	593	ref.	
>60	74	49	485	1.636 (0.962–2.780)	0.066
Missing	0				
<b>Gender</b>					
Female	53	36	511	ref.	
Male	59	33	592	0.855 (0.529–1.382)	0.523
Missing	0				
<b>Alcohol history<sup>b</sup></b>					
NO	43	25	592	ref.	
YES	61	38	511	1.276 (0.765–2.128)	0.349
Missing	8				
<b>History of diabetes<sup>c</sup></b>					
NO	68	44	511	ref.	
YES	24	12	603	0.873 (0.459–1.660)	0.679
Missing	20				
<b>History of chronic pancreatitis<sup>d</sup></b>					
NO	79	47	511	ref.	
YES	9	7	607	1.335 (0.600–2.970)	0.478
Missing	24				
<b>Family history of cancer<sup>e</sup></b>					
NO	31	19	458	ref.	
YES	79	25	603	0.873 (0.459–1.660)	0.923
Missing	42				
<b>Tumor size<sup>f</sup></b>					
≤2	4	1		ref.	
>2 and ≤4	76	47	511	2.266 (0.311–16.498)	
>4	30	21	592	2.202 (0.294–16.474)	0.708
Missing	2				
<b>Metastasis</b>					
M0	55	31	593	ref.	
MX	57	38	485	1.278 (0.787–2.075)	0.319
Missing	0				
<b>Pathologic stage</b>					
I	8	4	236	ref.	
II	104	65	518	1.038 (0.375–2.872)	0.943
Missing	0				
<b>Neoplasm histologic grade</b>					
G1+G2	80	45	596	ref.	
G3+G4	32	24	470	2.267 (0.962–5.341)	0.01
Missing	0				
<b>Targeted molecular therapy<sup>g</sup></b>					
NO	29	24	224	ref.	
YES	73	41	634	1.068 (0.095–0.296)	<0.001
Missing	10				
<b>Radiation therapy<sup>h</sup></b>					
NO	70	48	473	ref.	
YES	30	15	691	0.527 (0.293–0.947)	0.029
Missing	12				
<b>Residual resection<sup>i</sup></b>					
R0	66	39	63	ref.	
R1+R2	44	29	381	1.945 (1.174–3.223)	0.009
Missing	2				

<sup>a</sup>, Some of data in this table was included in our previous publication. <sup>b</sup>, Alcohol history is unavailable for 8 patients. <sup>c</sup>, History of diabetes is unavailable for 20 patients. <sup>d</sup>, History of chronic pancreatitis is unavailable for 24 patients. <sup>e</sup>, Family history of cancer is unavailable for 42 patients. <sup>f</sup>, Tumour size is unavailable for 2 patients. <sup>g</sup>, Targeted molecular therapy information is unavailable for 10 patients, <sup>h</sup>, Radiation therapy information is unavailable for 12 patients. <sup>i</sup>, Residual resection information is unavailable for 10 patients. HR, hazard ratio; MST, median survival time; OS, overall survival; PDAC, pancreatic ductal adenocarcinoma.